RE:RE:RE:RE:RE:RE:Quick and Dirty Sanity CheckRaguu17 wrote:
Your post was concervative. It only placed expectations on Sky, granted that is where the heavy lifting will occur. It didn't speak about the "war chest" and the possibilites. I have seen you and Bob betting on EU build. I think Quebec. I hope BOTH!!
Anyone curious where this comes from can look on Sedar - "Final Short Form Prospectus" dated Jan 2, 2018.
Business Objectives and Milestones
The Company’s primary business objectives over the next 12 months are:
1) Complete construction, obtain production and sales licenses and commence operations at Aurora Sky;
2) Increase production capacity and product line through construction of additional production facilities and entering into supply agreements;
3) Prepare for, an participate in, future adult recreational markets in Canada; and
4) Global expansion to sizable legal medical cannabis markets.
Significant events that need to occur for the business objectives to be accomplished:
1) Completion of construction and launch of operations at Aurora Sky:
a. Completion of phase 1 construction at Aurora Sky;
b. Receipt of production and sales license under Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”) for phase 1;
c. Recruitment and training of production staff and commencement of operations in January 2018;
d. Full construction completion by June 30, 2018;
e. Receipt of production and sales licenses under the ACMPR for dried cannabis and cannabis oils for the whole production facility and full operationalization; and
f. Spending approximately $47 million in construction costs out of the total estimated construction costs of $120 million.
2) Increase production capacity and product line through additional facility construction and supply agreements:
a. Complete construction at Aurora Vie and H2 production facilities in Quebec (the “New Facilities”). Minimal remaining capital expenditures are required to complete construction;
b. Receipt of production and sales license under the ACMPR for H2, and receipt of sales license under the ACMPR at Aurora Vie;
c. Recruitment and training of production staff at the New Facilities;
d. Commencement of operations at the New Facilities. Operations are expected to be launched during the first six months of 2018;
and e. Continue negotiation and execution of longer term cannabis supply agreements with third party licensed producers.
3) Preparation for, and participation in, the anticipated legalized adult recreational markets in Canada:
a. Expand and make investments in certain provinces in Canada by way of construction and/or acquisition of greenhouse facilities;
b. Build internal capacity for allowable marketing and branding, distribution channel management, and sales strategic planning;
and c. Continue to acquire additional products and services that will be important to the Canadian adult use market.
4) For global expansion to legal medical cannabis markets:
a. Continue to participate in the German production tendering process with results expected in the first quarter of calendar 2018;
b. Acquire a property and build a cannabis production facility in Germany if successful in the German Bid Process;
and c. Obtain the appropriate licenses to begin producing and selling medical cannabis in Germany;
d. Continue to export Canadian medical cannabis to the German market by obtaining the necessary export and import permits required to ship cannabis products from Canada to Germany until a German facility is constructed;
e. Continue to explore and negotiate production and distribution possibilities in other European countries with federally legal cannabis production and export framework and global jurisdictions. During the course of 2018, initiate construction of production facilities based on the Company’s strategic analysis;
and f. Costs are not estimable at the current time.